Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

0.2788 +0.0238 (+9.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ovid Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Ovid Therapeutics: Q1 Earnings Insights
Via Benzinga
Looking Into Ovid Therapeutics's Return On Capital Employed
Via Benzinga
Ovid Therapeutics: Q1 Earnings Insights
Ovid Therapeutics (NASDAQ:OVID) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Ovid Therapeutics Added to Russell 3000® Index
From Ovid Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
Via Benzinga
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
From Ovid Therapeutics Inc.
Via GlobeNewswire
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
From Ovid Therapeutics Inc.
Via GlobeNewswire
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
One executive called this the most "damaging" decision in five decades. 
Via Investor's Business Daily
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
Drugmakers Stand Up for Reproductive Rights: Pfizer and Biogen Among 300 Condemning Abortion Pill Approval Suspension
Via Benzinga
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
From Ovid Therapeutics Inc.
Via GlobeNewswire
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options 
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
From Ovid Therapeutics Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 94 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 149 companies reached new 52-week lows. 
Via Benzinga
3 Biotech Stocks Under $10 to Add to Your Buy List
These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. 
Via InvestorPlace
Overview Of Value Stocks In The Healthcare Sector
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback